森萱医药
(830946)
| 流通市值：50.10亿 | | | 总市值：50.12亿 |
| 流通股本：4.27亿 | | | 总股本：4.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 125,565,724.8 | 537,136,066.43 | 388,292,807.26 | 272,084,703.46 |
| 营业收入 | 125,565,724.8 | 537,136,066.43 | 388,292,807.26 | 272,084,703.46 |
| 二、营业总成本 | 89,563,161.4 | 384,117,079.97 | 280,612,605.13 | 188,944,959.26 |
| 营业成本 | 68,147,644.73 | 303,074,084.84 | 219,229,158.2 | 152,461,869.38 |
| 税金及附加 | 1,910,951.11 | 6,998,284.82 | 4,986,962.87 | 3,294,017.34 |
| 销售费用 | 3,753,124.26 | 14,481,608.19 | 11,348,175.29 | 7,791,238.66 |
| 管理费用 | 13,740,994.41 | 57,542,288 | 41,365,002.22 | 26,664,981.54 |
| 研发费用 | 4,548,782.88 | 28,636,950.09 | 22,856,171.16 | 14,524,720.34 |
| 财务费用 | -2,538,335.99 | -26,616,135.97 | -19,172,864.61 | -15,791,868 |
| 其中:利息费用 | 11,797.95 | 583,687.08 | 535,558.76 | 452,080.41 |
| 其中:利息收入 | 2,654,133.72 | 25,244,158.81 | 20,303,787.34 | 14,997,440.81 |
| 加:公允价值变动收益 | 484,059.14 | 1,464,962.91 | 1,386,469.86 | 1,138,358.75 |
| 加:投资收益 | 48,647.26 | 1,198,523.11 | 957,391.69 | 769,225.02 |
| 资产处置收益 | - | -190,269.32 | - | - |
| 资产减值损失(新) | -2,424,771.3 | -8,250,382.13 | -228,657.89 | -889,544.95 |
| 信用减值损失(新) | 638,867.84 | -2,369,004.11 | -613,608.27 | -1,386,165.2 |
| 其他收益 | 780,324.46 | 4,978,251.4 | 2,824,326.02 | 2,362,595.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 35,529,690.8 | 149,851,068.32 | 112,006,123.54 | 85,134,213.28 |
| 加:营业外收入 | - | 1,600,678.96 | 7,002.39 | 6,001.2 |
| 减:营业外支出 | - | 4,240,098.05 | 3,433,430.92 | 2,532,740.92 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 35,529,690.8 | 147,211,649.23 | 108,579,695.01 | 82,607,473.56 |
| 减:所得税费用 | 5,307,652.93 | 21,553,561.59 | 14,954,789.36 | 11,913,912.49 |
| 六、净利润 | 30,222,037.87 | 125,658,087.64 | 93,624,905.65 | 70,693,561.07 |
| 持续经营净利润 | 30,222,037.87 | 125,658,087.64 | 93,624,905.65 | 70,693,561.07 |
| 归属于母公司股东的净利润 | 29,032,478.96 | 123,759,884.41 | 91,366,685.53 | 69,680,607.02 |
| 少数股东损益 | 1,189,558.91 | 1,898,203.23 | 2,258,220.12 | 1,012,954.05 |
| (一)基本每股收益 | 0.07 | 0.29 | 0.21 | 0.16 |
| (二)稀释每股收益 | 0.07 | 0.29 | 0.21 | 0.16 |
| 九、综合收益总额 | 30,222,037.87 | 125,658,087.64 | 93,624,905.65 | 70,693,561.07 |
| 归属于母公司股东的综合收益总额 | 29,032,478.96 | 123,759,884.41 | 91,366,685.53 | 69,680,607.02 |
| 归属于少数股东的综合收益总额 | 1,189,558.91 | 1,898,203.23 | 2,258,220.12 | 1,012,954.05 |
| 公告日期 | 2025-04-29 | 2025-04-14 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |